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Abstract: Complementary and alternative treatment approaches are becoming more common among
children with chronic conditions. The prevalence of CAM use among US adults was estimated to
be around 42% in 2015 and around 44% to 50% among adults with neurologic disorders. Studies
demonstrate that children with certain chronic illnesses such as asthma, cancer, genetic disorders,
attention-deficit/hyperactivity disorder (ADHD), and other neurodevelopmental disorders are
treated with complementary and alternative treatments at higher rates. Dietary therapies are gaining
increasing popularity in the mainstream population. Although the majority of “fad” diets do not
have enough supporting evidence, some dietary therapies have been utilized for decades and have
numerous published studies. The objective of this review is to describe the dietary interventions used
in children with the specific chronic conditions, to evaluate their efficacy based on published data
and to encourage pharmacist involvement in the management and care of such patients.
Keywords: pediatric pharmacy; complementary alternative medicine; dietary interventions; oral
manifestations; chronic pediatric conditions; ketogenic diet; gluten free casein free diet
1. Introduction
Complementary and alternative treatment approaches are becoming more common among
children with chronic conditions. The National Center for Complementary and Alternative Medicine
at the National Institute of Health (NIH) defines complementary and alternative medicine (CAM)
as a “group of diverse medical and health care systems, practices, and products that are not
presently considered to be part of conventional Western medicine” [1]. CAM treatments may
be used in combination with traditional treatment approaches (complementary) or in place of
traditional treatments (alternative), which is less common. There are various categories of CAM,
such as biologically-based (e.g., herbs, vitamins, diets), manipulative and body-based (e.g., massage,
chiropractic), mind–body (e.g., hypnosis, prayer), and biofield (e.g., acupuncture, homeopathy).
The prevalence of CAM use among US adults was estimated to be around 42% in 2015 and around
44% to 50% among adults with neurologic disorders [2,3]. The NIH Center for Complementary
and Integrative health estimated the use of CAM among US children to be at 11.6%, with natural
products (fish oil/omega-3, melatonin, and probiotics) being the most commonly used [1]. Special
diets accounted for 0.8% of CAM’s used and 2.2% of US children with conditions like ADHD used
some form of CAM [1]. Other studies demonstrate that children with certain chronic conditions
such as attention-deficit/hyperactivity disorder (ADHD) and other neurodevelopmental illnesses,
utilize CAM at higher rates (24%) [4–7]. Among those, supplement and herbal medications, as well
as dietary modifications (i.e., elimination or intake of specific foods) are most prevalently used at
31% and 17% respectively [7]. Many natural products, such as fish oil/omega-3 and probiotics,
are well supported by studies for their place in the prevention and treatment of certain conditions
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in both adults and children. The various reported reasons for use of CAM by adults and caregivers
of children include fear of adverse effects from conventional medications and perception of safety
compared to traditional medicine. Parents of children with conditions that lack effective medical
approaches or complete remissions often turn to alternative treatment approaches with the notion
that they are generally risk-free. A survey of parents found that more than 50% had used at least on
type of CAM therapy for their children with ASD, which is not always reported to the health-care
provider [8,9]. Dietary therapies are gaining increasing popularity in the mainstream population,
as families may seek advice from health practitioners such as naturopathic doctors, chiropractors and
acupuncturists or lay advisers within their cultural communities [1]. Although the majority of “fad”
diets do not have enough supporting evidence, some dietary therapies have been utilized for decades
and have numerous published studies. Special diets, such as the ketogenic and the low-FODMAP
diet, are commonly used as an alternative to conventional treatment, while most exclusion diets are
utilized as a complement to their conventional treatment plans. Specific diets are discussed in detail
below. Nevertheless, CAM approaches, such as dietary interventions, pose potential challenges when
integrated with conventional treatments as well as with the risk of adverse effects. For those patients
who are undergoing integrative treatment, close collaborative management from health-care providers
is essential in ensuring the success of therapy and the well-being of the patient.
The objective of this review is to describe the dietary interventions used in children with the
specific chronic conditions, to evaluate their efficacy based on published data, and to encourage
pharmacist involvement in the management and care of such patients.
2. Review of the Literature
The literature review below was compiled using a systematic search of Medline database [10] from
years 1975 to 2018. The search criteria included articles published in English language and restricted to
human studies. Key words searched were combinations of complementary, alternative, diet, dietary,
neurodevelopment, pediatric, naturopathy, homeopathy, IBS, Crohn’s, ADHD, ASD or chronic. Articles
were selected based on the design, methodology and evaluation, and included randomized controlled
trials (RCT), meta-analyses and review articles. Conditions and applicable diets were selected based
on the availability of RCT’s and meta-analyses, as well as the applicability to the pharmacy profession.
Figure 1 provides an overview of the literature selection process. The search identified a total of
255 publications with the inclusion of a combination of the above search terms. Following the removal
of 189 irrelevant records, based on the established exclusion criteria, 66 publications remained. Of these,
39 were excluded as they did not meet the selection criteria, and 16 were removed based on its relevancy
to the selected diets. As a result, a total of 11 studies are being included in this review.
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Figure 1. PRISMA Flow Diagram.
3. Ketogenic Diet for Epilepsy
Epilepsy is a group of neurologic disorders characterized by episodes of recurring seizures,
the cause of which is mostly unknown. Despite continued advancements in anticonvulsant
pharmacotherapy, 30% of patients with epilepsy experience refractory seizures that are unresponsive
to pharmacologic treatment or become intolerant to the side effects of medications [11]. The ketogenic
diet (KD) is a non-pharmacologic treatment option for children with refractory seizures, which has
been used worldwide for decades. The Ketogenic Diet Study Group, which is comprised of dieticians
and other specialists in pediatrics, had published a consensus report outlining that the KD may be
strongly considered in children with symptomatic generalized epilepsies who had failed two to three
anticonvulsant therapies [12].
Fasting has been utilized since the 1920’s to alleviate symptoms of seizures, although the exact
mechanism of action was not yet known at the time. It was believed that an intoxication of the brain
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from substances in the intestines was the main cause of epilepsy and fasting was reported to have high
rates of efficacy [13]. It was later discovered that ketones were responsible for the anticonvulsant effect
of fasting and can be produced in the absence of sufficient glucose through the oxidation of certain
acids. Such acids are produced when the body consumes mainly fats as its primary energy source and
therefore mimicking a state of fasting, thereby being termed the ketogenic diet. The ketogenic diet (KD)
for the treatment of epilepsy was first reported in 1921 and has been studied extensively since [14].
The diet consists of mainly fat and protein consumption, with very low intake of carbohydrates
(e.g., 4:1, 3:1, or 2:1 fat to non-fat ratio). Energy consumption mainly from fat is thought to mimic
a state of ketosis. Fat metabolism through the liver leads to the production of three ketone bodies:
beta-hydroxybutyrate (BHB), acetoacetate and acetone, which cross the blood-brain barrier and become
the brain’s primary energy source [15].
Although not completely understood, several theories exist regarding the mechanism of action
of the KD. It has been proposed that utilization of ketones for energy metabolism in the brain
results in adaptive changes which increase energy reserves and gamma-aminobutyric acid (GABA)
synthesis (major inhibitory neurotransmitter), resulting in seizure resistance [16]. Ketone bodies
themselves are thought to possess anticonvulsant properties since they are structurally similar to
GABA, BHB and acetoacetate. The diet has also been documented to be neuroprotective by inhibition
of caspase-3-mediated apoptosis and through the activation of mitochondrial uncoupling proteins,
which can reduce the production of reactive oxygen species [16].
The ketogenic diet encompasses various modalities of implementation, however, the majority
of clinical data available are for the classic KD, which consists of 90% caloric intake from long-chain
triglycerides and only 10% from carbohydrates and proteins, in a 4:1 ratio of fat to non-fat sources [16].
The classic KD is recommended for children, however, a 3:1 ratio for adolescents and a 2:1 ratio for
infants may be used since more protein is required in these age groups [16]. Liquid KD formulas
are available for bottle-fed infants and children with gastrostomy tube feedings. The diet is further
modified to allow for appropriate growth and development of a child. Initiation of the KD most often
takes place in an acute care setting, at an outpatient epilepsy center or as an inpatient at a hospital,
in order to safely monitor ketone and glucose levels, with an average hospital stay of 4 days [17].
The diet is traditionally introduced slowly following a 24–48 h fasting period, until the patient fully
tolerates the KD and is then discharged home.
The efficacy of the KD on seizure activity in published studies varies, although the majority
of studies show some reduction in seizure occurrence. A recent meta-analysis, which included
19 observational studies with a total of 1084 patients, found that close to 60% of patients had over a
50% seizure reduction, while 30% had over a 90% reduction in seizures, 6 months after initiation of the
KD [17]. A randomized controlled trial including 145 children reported that the mean percentage of
baseline seizures was significantly lower in the KD group at 3 months compared to the control group,
which had experienced an increase in seizures from baseline [18].
Variations of the KD exist; although the most commonly utilized is the classic KD,
the medium-chain triglyceride (MCT) diet, the modified MCT diet, the modified Atkins diet,
and the low-glycemic index treatment diet can also be utilized. The MCT diet is comprised of
mainly medium-chain fatty acids at 71% (as a specially formulated oil), 10% protein, and 19%
carbohydrates [17]. The MCT is comprised of fat sources that produce more ketones than the long-chain
triglycerides (LCT) used in the classic KD, therefore allowing for less fat consumption and more protein
and carbohydrates to be incorporated into the diet [17]. Alternatively, the modified MCT diet combines
the use of LCT (40–50% of calories) and MCT (30% of calories), as well as protein (10–20%) and
carbohydrates (5–10%). A study comparing the MCT diet, classic KD, as well as a modification of both,
reported that they were of approximately equal efficacy, with a higher incidence of gastrointestinal
irritation with the MCT diet [17]. The modified Atkins diet (MAD) and low-glycemic-index (LGID)
treatment diet both can utilize medium-chain or long-chain triglycerides (65% calories from fat), with a
larger daily allowance of carbohydrate intake, which offers more flexibility in meal preparation to
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the caregiver [19]. These diets can be initiated in an outpatient setting. A study of 20 patients with
retractable epilepsy on a modified Atkins diet showed greater than 50% reduction in seizures at
6 months in the majority of patients [20]. These results closely correlate to the efficacy of the classic KD.
Although generally considered to be a safe treatment choice, KD has been shown to cause
several adverse events in children and adults. During initiation of the diet, acidosis, dehydration,
hypoglycemia, and gastrointestinal distress have been reported as the most prominent adverse events
but are typically transient and easily managed [12]. Other reported adverse events associated
with the KD maintenance include poor growth, nephrolithiasis, dyslipidemia, prolongation of
QT interval, cardiomyopathy, excessive bruising, vitamin D deficiency, trace mineral deficiencies,
constipation, and exacerbation of gastrointestinal reflux disease [12]. Cholesterol and lipids have been
shown to be adversely affected, with a reported increase of total cholesterol of ~130%, which then
stabilized over 2 years [12]. Certain conditions, such as the history of kidney stones, liver disease,
dyslipidemia, gastroesophageal reflux disease, cardiomyopathy, constipation, or metabolic acidosis,
may be aggravated by the diet and require close monitoring and testing [12].
Serious complications associated with the KD appear to be relatively rare, while the long-term
complications are not well documented [21]. Overall, the KD can be an appropriate treatment option
for epilepsy in children, and as with any other medical treatments, requires individualized care,
close monitoring, and follow-up by the health-care provider.
Pharmacists can play an important role in the management of patients on the KD and concomitant
pharmacologic therapy. Many medications, specifically pediatric liquid preparations, have a high
carbohydrate content, which may compromise ketosis. Anticonvulsants medications with the highest
amounts of carbohydrates include carbamazepine suspension, phenobarbital elixir, ethosuximide
syrup, and valproic acid syrup, and should be limited or avoided in children on the KD [22].
Alternatively, these patients may be given the capsule or crushed tablet formulation, which generally
contains very low amounts of carbohydrates. For a summative list of common pediatric medications
with high carbohydrate content refer to Table 1. Despite a long history of concomitant use of the KD
and antiepileptic agents, evidence is insufficient to conclude what negative or positive drug interactions
are of concern, and limited information exists regarding the effects of KD on pharmacokinetics of
antiepileptics. Abnormal laboratory parameters may be seen in children on KD; however, metabolic
acidosis requiring treatment may be more common with the concomitant use of topiramate or
zonisamide, particularly at the initiation of KD [12]. Bicarbonate concentrations need to be closely
monitored, particularly in the presence of concomitant anticonvulsant administration. Additionally,
supplements containing bicarbonate should be reserved for patients who are clinically symptomatic
(e.g., vomiting, lethargy) [12].
Table 1. Common pediatric medications with high carbohydrate content (≥2 grams/dose) [22] *.
Dosage Unit
Acetaminophen liquid suspension (cherry) (Tylenol) 160 mg/5 mL
Acetaminophen elixir with codeine (Tylenol with Codeine) × 0.35 g ethyl alcohol/5 mL 120 mg/5 mL
Amoxicillin oral suspension (Trimox) 125 mg/5 mL
Ampicillin oral suspension (Omnipen) 125 mg/5 mL
Carbamazepine suspension (TEGretol) 100 mg/5 mL
Cephalexin oral suspension (Keflex) 125 mg/5 mL
Phenobarbital elixir ×0.71 g ethyl alcohol/5 mL 20 mg/5 mL
Valproic acid syrup (Depakene) 250 mg/5 mL
* For a more comprehensive list of medications refer to article reference [22].
4. Gluten-Free Casein-Free Diet for Autism Spectrum Disorder
Prevalence of autism and autism spectrum disorder (ASD) has been on the rise and was most
recently reported to occur in 1 in 59 US children [23]. According to the Diagnostic and Statistical
Manual of Mental Disorders, Fifth Edition “autism is characterized by qualitative impairments in
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social interaction and communication, as well as restrictive, repetitive, and stereotyped patterns of
behavior, interest and activity” [24]. The most recent updates to the manual include the combining of
autism subtypes, such as autistic disorder and Asperger syndrome, into a unified diagnosis of autism
spectrum disorder (ASD) [24,25].
Definitive etiology of ASD is not yet clearly understood since several studies attribute the disorder
to genetic factors, metabolic derangements and environmental or dietary causes [26]. Gastrointestinal
issues, such as chronic constipation or diarrhea, are among the most common medical conditions
associated with autism, although a direct correlation has not been substantiated. A study comparing
GI issues in children with autism and other neurodevelopmental illnesses (e.g., cerebral palsy)
found that 70% of children with autism were affected compared with 42% of children with other
neurodevelopmental illnesses and 28% of children with normal development [27]. In a study conducted
by Campbell et al., 9% of unaffected siblings of children with ASD had a gastrointestinal disorder
whereas the prevalence in children with autism was at 41% (p = 0.000) [28]. Considering the proposed
etiology of GI involvement in ASD, many research articles have been published looking at dietary
interventions to alleviate symptoms in children with ASD.
Specific dietary interventions in children with ASD include the omission of gluten and
casein-containing foods [29]. The prevalence of use of the gluten-free and casein-free diet (GFCF)
among children with ASD is estimated at 40% [30]. Gluten is a protein found in wheat, rye and barley,
whereas casein is a protein found in dairy products [31]. The cessation of gluten and casein is based
on the theory that opioid peptides may be produced due to a partial breakdown of foods that have
gluten and casein. Such peptides can cross into the systemic circulation due to the increased intestinal
permeability in children with ASD and further affect brain function and development [31]. Therefore,
avoidance of foods containing gluten and casein is suggested to alleviate behavioral symptoms
associated with ASD. Although widely reported and used, the diet and its proposed etiology lacks
substantial evidence for efficacy, with only a few well-designed trials published.
Although anecdotal reports from parents of success with the diet flood online forums, scientific
evidence for its effectiveness remains inconclusive. A systematic review conducted in 2008 summarized
two randomized controlled trials evaluating gluten-free casein-free (GFCF) diets in children with
ASD [31]. While one of the studies concluded the GFCF diet significantly reduced the severity
of symptoms of autism, the other study found no difference in the outcomes [31]. A recent
randomized-controlled trial studied children with ASD who were assigned to either a GFCF diet
or a low-sugar diet for 3 months in an open-label design [32]. No statistically significant differences
were found between groups, although some behavioral and developmental benefits were observed
in the GFCF group [32]. A study published in 2013 utilized a research synthesis technique to review
major articles published on the use of GFCF diet in children with ASD [33]. In their assessment,
the authors identified most studies that did not support the use of the GFCF diet in ASD and presented
various limitations in the study design of the trials. Additionally, they noted most studies incorporated
GFCF with other treatment modalities making it difficult to assess the effectiveness of GFCF alone,
and subpopulations including Rett Syndrome and Childhood Disintegrative Disorder (CDD) require
further studies to determine efficacy [33]. Overall, the American Academy of Pediatrics does not
recommend the use of GFCF for ASD due to the lack of sufficient evidence, while the United Kingdom
2013 National Institute for Health and Care Excellence (NICE) clinical guideline on the management of
ASD suggests that the potential risks of GFCF outweigh their benefits [34,35].
The majority of studies on GFCF did not report any serious adverse effects from the diet. However,
an observational study on the provision of GFCF suggests casein restriction may lead to decreased
bone mass and essential amino acid deficiency, such as tryptophan [36]. It is important for health-care
providers to counsel families on the need for adequate vitamin D, calcium and protein supplementation,
since most milk substitutes do not contain the appropriate amounts of protein. Another potential
harm of adopting a GFCF diet is the potential to overlook possible underlying celiac disease or lactose
intolerance [36]. Celiac disease is the most common autoimmune gastrointestinal disorder for which
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the treatment is complete avoidance of gluten [36]. Pharmacists should be aware of medications that
may contain gluten as an excipient and be able to recommend alternative agents for patients with
celiac disease or on a GFCF/gluten-free diet. For a list of common medication excipients containing
gluten, as well as resources to find information regarding gluten-free medications, refer to Tables 2
and 3.
Table 2. Common Medication Excipients that May Contain Gluten [37,38].
Excipient Gluten-Free Botanical Source Gluten ContainingBotanical Source
Starch Corn, potato, tapioca Wheat
Pregelatinized starch, pregelatinized
modified starch, sodium starch glycolate Corn, rice, potato Wheat
Dextrans Corn, potato Wheat, barley
Dextrose Corn Wheat, barley
Dextrates, dextrins Corn, potato Wheat, barley
Maltodextrin Corn, potato Wheat, barley
Caramel coloring Corn Barley malt
Table 3. Resources for more information about gluten in medications.
List of medications verified to be gluten-free www.glutenfreedrugs.com
“A guide through the Medicine Cabinet” (book) In print
Walgreens and CVS pharmacy OTC brand medication list Available upon request
Additional information on gluten in foods and products www.celiac.orgwww.celiaccentral.org
5. Specific Carbohydrate Diet (low FODMAPs) for Irritable Bowel Syndrome
Functional gastrointestinal disorder (FGID) is defined as a variable combination of chronic or
recurrent gastrointestinal symptoms such as diarrhea, constipation and abdominal pain, which cannot
be attributed to another medical condition [39]. Types of FGID include irritable bowel syndrome (IBS),
functional abdominal pain, functional dyspepsia and abdominal migraine, with IBS being the most
common [39]. The etiology of FGID is poorly understood, however, food intolerance such as poor
absorption of carbohydrates has been implicated in the pathogenesis of FGID with recently emerging
studies [40]. Most symptoms of irritable bowel syndrome (IBS) are due to luminal distension of the
distal small and proximal large intestine, causing pain, bloating and abdominal distension, while some
may also present with oral lesions, which are commonly missed upon diagnosis [41,42]. Solid, liquid
or gas materials present in the gut can promote the distension of the lumen. Solids, mostly in the form
of fiber, can either expand or contract the bacterial mass of the gut. Liquids may dictate the osmotic
absorption or retention in the lumen, while gas can be ingested in the form of excess nitrogen, but is
mostly produced by bacterial fermentation [42]. Therefore, dietary components that may lead to these
changes in the lumen of the intestine are generally poorly absorbed, are small molecules, and can be
readily fermented by bacteria.
Fermentable Oligo-, Di- and Monosaccharides and Polyols (FODMAPs), are short-chain
carbohydrates and sugar alcohols (polyols) which comprise fructose, lactose, fructo- and
galactooligosaccharides (i.e., fructans, galactans), and polyols (e.g., sorbitol, mannitol, xylitol,
maltitol) [42]. These dietary components have three common properties: they are poorly absorbed in
the small intestine, they are small and osmotically-active molecules, and they are rapidly fermented
by bacteria. For a list of High-FODMAP food sources, refer to Table 4. All of these properties can
potentially contribute to the exacerbation of FGID symptoms. Thus, a low-FODMAP diet can improve
gastrointestinal symptoms by reducing the amount of undigested carbohydrates in the presence of
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colonic bacteria, leading to less fermentation, which can lead to decreased abdominal bloating and
pain as well as flatulence [43].
Numerous studies in adults have demonstrated significant improvement of IBS symptoms in
patients on the low FODMAP diet, showing significantly higher satisfaction with stool consistency
and decreased abdominal pain, bloating and flatulence [44]. Limited studies exist, however, for the
use of the low FODMAP diet in children with IBS. Two studies, with limited power, studied the effects
of fructose on the GI tract and elimination of fructose in children with fructose malabsorption [45,46].
The studies indicated that the administration of fructose produced a positive hydrogen breath test
in 11 out of 32 children and fructose elimination was effective in reducing functional abdominal
pain symptoms in 77% of studied children [45,46]. A double-blind randomized controlled trial of
54 children with IBS looked at a low-FODMAP diet compared to a high-FODMAP diet using a
crossover design [47]. The authors found fewer episodes of abdominal pain, less nausea, less bloating
and lower breath hydrogen production after 2 days on the diet [47]. Further studies in children are
warranted to confirm the efficacy of the low-FODMAP diet for IBS and to determine its value in other
forms of FGID.
Although limited, reports regarding the safety of the low-FODMAP diet indicate that certain risks
exist. Due to the limited ingestion of foods that are considered prebiotics, the gut microflora may be
diminished, which could potentially be detrimental to large bowel health (e.g., promotion of colorectal
carcinogenesis) [48]. The lack of fiber intake could arise from restricted intake of wheat-containing
foods. In adolescents, the possibility of eating disorders comes into play, as a result of the innate
possibility of IBS or food restrictions with the diet [48]. Close monitoring and counseling by a dietician
is essential to ensure compliance and positive outcomes with the diet. For the patients who are on the
diet, it is important for pharmacists to consider the presence of fructose or lactose in some pediatric
drug formulations that may potentially worsen symptoms as well as counsel on the importance of
vitamin and mineral supplementation.
Table 4. High-FODMAP Carbohydrate Food Sources (to be avoided) [49].
Fructo-oligosaccharides (fructans) Wheat, rye, onions, garlic, artichokes
Galacto-oligosaccharides (GOS) Legumes
Lactose Milk and milk products
Fructose Honey, apples, pears, watermelon, mango
Sorbitol Apples, pears, stone fruits, sugar-free mints/gums
Mannitol Mushrooms, cauliflower, sugar-free mints/gums
6. Dietary Interventions for ADHD
Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental condition
present among school-age children. According to the American Psychiatric Association’s Diagnostic
and Statistical Manual, Fifth edition (DSM-5), ADHD is distinguished by symptoms of inattention,
overactivity, and/or impulsiveness which are age inappropriate, persistent, and pervasive [50,51].
ADHD presents with a probable future risk of school difficulties, communication challenges, mental
illness and delinquency, which puts a significant load on families, as well as on the social and health
care systems [52].
Generally, pharmacologic treatments for management of ADHD are preferred and widely used;
however, a multimodal approach to treatment is recommended. A variety of non-pharmacologic and
dietary interventions for the management of ADHD have been studied with mixed results. One of
the earliest studied dietary interventions for ADHD is the Feingold diet, which was introduced in the
1970’s by Dr. Feingold who believed certain additives in food were associated with hyperactivity [53].
Foods avoided on the Feingold diet include processed meats, apples, grapes, and drinks with artificial
flavors and coloring agents [53]. Products containing red and orange synthetic dyes, as well as
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preservatives like butylated hydroxytoluene and butylated hydroxyanisole are advised against [53].
The diet gained popularity when initially introduced to physicians and was claimed to ameliorate
symptoms in more than 50% of children treated for hyperactivity [54]. Several controlled studies
performed since failed to show the same efficacy; however, a small subgroup of children that may be
susceptible have been identified [54]. More recent versions of the diet recommend avoiding artificial
food coloring and additives only [55].
A meta-analysis published in 2012 evaluated studies on restriction diets for ADHD, in particular,
elimination of artificial food coloring [56]. From the 34 high-quality studies selected, the authors
published that while parent reports yielded a statistically significant reduction in symptoms among
patients who eliminated food dyes, teacher/observer reports yielded no significant effect [56].
This illustrates the concept of observer bias, since parents are more likely to think an intervention is
helping their child, therefore influencing the results. The authors concluded that an estimated 8% of
children with ADHD may have symptoms related to synthetic food dyes and that further studies are
warranted [56].
Another commonly used dietary intervention for children with ADHD is an oligoantigenic
(hypoallergenic/elimination) diet. Oligoantigenic diet eliminates most known sensitizing food
antigens or allergens, such as cow’s milk, cheese, wheat cereals, egg, chocolate, nuts, and citrus fruit,
in an effort to identify and manage food allergies and intolerances that may be linked to neurologic
dysfunction [57]. More recently known as an “elimination diet”, these diets may vary in their specific
contents. A multi-food elimination diet, such as the 6-food elimination diet, excludes most food
allergens. Alternatively, a “few foods diet” consists of consuming only foods with low antigenic
potential, such as lamb/venison, quinoa/rice, pear, and a few others [58]. Individuals on a “few foods
diet” must be closely monitored by a dietician to avoid nutritional deficiencies. Most elimination
diets follow a two-step process, where foods are excluded for a period of time, after which foods are
reintroduced one at a time to identify those that are causing symptoms [59].
Two recent meta-analyses were conducted to evaluate the diet effects of both
restriction/elimination diets and food coloring agents on symptoms of ADHD. The authors
concluded that the diet effect on children with ADHD, especially those with severe symptoms,
can be higher than in those without ADHD, and that elimination diets might work. However,
both meta-analyses noted the questionable study methods in most evaluated studies, as well as the
difficulty in generalizing symptom improvement [56,60].
Overall, data on the effectiveness of elimination diets are conflicting and require additional,
well-designed studies with a large sample size. For those parents of children with ADHD who do
choose to implement elimination diets in their treatment regimen, pharmacists are able to assist
with the proper selection of medication excipients. Many liquid pediatric formulations contain food
dyes, artificial sweeteners, as well as allergens. By identifying the origin of the excipient in the
prescribed or over-the-counter medications, pharmacists can help patients avoid those triggers and
maintain their diet regimen. While many over-the-counter pediatric formulations are available as a
dye-free alternative, pharmacists can be a great resource to locate information regarding food dyes
and sweeteners used for prescription medications and flavoring agents. Although many prescription
medications may list dyes and sweeteners in the excipient list, some dyes may be present in binding
agents, which may not be found in the package insert. In the instance of absent information regarding
dyes, it is recommended for the pharmacist to contact the manufacturer directly.
7. Conclusions
Neurodevelopmental disorders are complex in nature, and their pathophysiology is not yet
completely understood. Due to the challenges with the selection of the appropriate pharmacologic
management, complementary and alternative treatment modalities are becoming more common among
pediatric patients. Many parents feel that dietary interventions are a safe alternative, especially in the
cases of conventional treatment failure. Although generally considered safe, dietary interventions
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do pose certain risks and require proper management. Pharmacists can play an important role in
education of pediatric patients and their parents on the safety and efficacy of various CAM therapies
as well as in managing their diets and preventing adverse effects (Appendix A). Communication
with patients continues to prove its importance in many facets of pharmacotherapeutic management,
but is ever more valuable for those patients also utilizing complementary and alternative therapies.
The majority of the dietary interventions mentioned in this article do not have enough evidence to
support use as monotherapy. Therefore, larger and better-structured studies are necessary to further
identify their place in the management of chronic disorders in children.
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Appendix A
Table A1. Overview of the characteristics of the respective dietary interventions.
Diet Diet Modality TargetCondition Evidence
Potential Adverse
Effects
Pharmacist
Considerations
Ketogenic
Classic
MCT
Modified Atkins
LGI
Calories from 90% fat
and 10% carbohydrate
and proteins
Medium-chain
triglycerides
Long-chain triglycerides
Refractory
Epilepsy
RCT’s and
meta-analyses available
show statistically
significant positive
results [16,17]
Vomiting, diarrhea,
acidosis, dehydration,
hypoglycemia, poor
growth, kidney stones,
vitamin deficiency, etc.
Monitor carbohydrate
content in liquid
formulations;
bicarbonate levels;
concomitant
anticonvulsants
Gluten-free
Casein-free
Exclusion of gluten and
casein (e.g., products
containing wheat, oats,
barley, or rye; and milk
and dairy products)
ASD
Results are inconclusive
with weak evidence for
positive effects. A subset
of patient with GI
disturbances may
benefit [30–34]
Potential decrease in
bone mass; deficiencies
in essential amino acids,
vitamin D, calcium,
and protein
Counseling on vitamin
supplementation;
availability of
gluten-free medications
(both OTC and Rx)
Low FODMAPs
Exclusion of short-chain
carbohydrates (wheat,
rye, garlic, legumes, etc.)
and sugar alcohols
(mannitol, sorbitol, etc.)
IBS
Results are inconclusive
with weak evidence for
positive effects. Diet did
show improvement in
symptoms such as
bloating, nausea, and
abdominal pain. [39,40]
Diminished microflora;
lack of fiber intake
leading to constipation;
possible effect on
growth; eating disorders
Counseling on vitamin
supplementation;
monitor for presence of
high-FODMAP
excipients in
medications
(both OTC and Rx)
Feingold
Oligoantigenic
Elimination of artificial
food coloring, flavors,
fragrances, preservatives
and sweetners.
Elimination of antigenic
foods (diet restricted to
hypoallergenic foods:
turkey, pears, rice,
lettuce, water)
ADHD
Meta-analyses showed
weak or no evidence for
positive effects. Children
with severe ADHD may
experience larger effects
on symptom
resolution. [58–60]
Possible vitamin,
mineral, fiber and
protein deficiencies
Counseling on vitamin
supplementation;
selection of medications
without artificial dyes
or sweeteners.
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